Menu Search
Equities

Median Technologies SA

4ZG:STU

Median Technologies SA

Actions
  • Price (EUR)4.19
  • Today's Change-0.05 / -1.18%
  • Shares traded0.00
  • 1 Year change-2.90%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Median Technologies SA is a France-based company that publishes software for the diagnosis and monitoring of cancer patients. The Company develops lesion management solutions (LMS) to objectively measure and track cancerous or suspicious lesions, distribute a standardized oncologic report and centralize the lesion information for multidisciplinary review. The LMS line includes such products as LMS-Lung, a clinical application for the detection, evaluation and follow-up of lesions identified in CT images covering the chest; LMS-Track, a clinical application for the follow-up of oncology patients; and LMS-Liver, a clinical application for the initial evaluation and the follow-up of liver metastases and any other lesions identified in CT images covering the liver. The Company operates one subsidiary, Median Technologies Inc, based in the United States.

  • Revenue in EUR (TTM)21.84m
  • Net income in EUR-25.35m
  • Incorporated2002
  • Employees250.00
  • Location
    Median Technologies SALes Deux Arcs - Batiment B 1800Route des CretesVALBONNE 06560FranceFRA
  • Phone+33 493333777
  • Fax+33 492906599
  • Websitehttps://mediantechnologies.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.